Effect of Indapamide on Urinary Calcium Excretion in Patients with and without Urinary Stone Disease

Abstract

Spanish

French

BACKGROUND:

Indapamide is an antihypertensive agent similar to thiazides, but with some different effects. Thiazide and thiazide-like diuretics are useful in preventing recurrent urinary stone formation due to their hypocalciuric effects.

OBJECTIVE:

To determine the hypocalciuric and other effects on certain laboratory parameters of indapamide 1.5 mg in different patient groups.

METHODS:

Four groups of patients recruited from urology and nephrology outpatient departments were experiencing non-hypercalciuric urinary stone disease (group 1), idiopathic hypercalciuria (group 2), urinary stone disease with hypercalciuria (group 3), and essential hypertension (group 4). In all patients, fasting serum uric acid, calcium, sodium, potassium, cholesterol, triglyceride, parathyroid hormone (PTH) values, and morning second-spot urine calcium and creatinine levels were assessed before and 8 weeks after treatment with indapamide.

RESULTS:

Urinary calcium excretion was reduced significantly in all groups: group 1 from 0.10 ± 0.02 to 0.07 ± 0.03 (mean ± SD; 30% reduction; p < 0.001), group 2 from 0.30 ± 0.15 to 0.15 ± 0.10 (50% reduction; p < 0.001), group 3 from 0.35 ± 0.15 to 0.20 ± 0.10 (43% reduction; p < 0.001), and group 4 from 0.10 ± 0.03 to 0.08 ± 0.02 (20% reduction; p < 0.0010). These results should be interpreted with caution since no control group was included in this study. Mean serum uric acid and triglyceride levels were significantly increased, and mean PTH and potassium levels and diastolic and systolic blood pressure were significantly decreased in all groups. Few temporary adverse effects, such as dizziness and fatigue, were noticed and none of them caused discontinuation of treatment.

CONCLUSIONS:

Indapamide 1.5 mg/day is effective in decreasing calciuria in patients with non-hypercalciuric urinary stone disease, idiopathic hypercalciuria, urinary stone disease with hypercalciuria, and essential hypertension. This could be achieved with few adverse effects similar to those of thiazides and indapamide 2.5 mg. Indapamide decreased the PTH levels in all groups. Long-term clinical benefits of these effects should be evaluated prospectively with further randomized studies.

Keywords

hypercalciuria hypertension indapamide urinary stone disease

Get full access to this article

View all access options for this article.

References

Coe

Parks

Asplin

. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327: 1141–52.

Borghi

Schianchi

Meschi

Guerra

Allegri

Maggiore

. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346: 77–84.

Parmar

. Kidney stones. BMJ 2004; 328: 1420–4.

Nijenhuis

Hoenderop

Loffing

van der Kemp

van Os

Bindels

. Thiazide-induced hypocalciuria is accompanied by a decreased expression of Ca²⁺ transport proteins in kidney. Kidney Int 2003; 64: 555–64.

Cohen

Madhavan

Alderman

. High and low serum potassium associated with cardiovascular events in diuretic-treated patients. J Hypertens 2001; 19: 1315–23.

Ward

. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352: 670–1.

Houston

. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J 1988; 115: 640–56.

Ames

. The influence of non—beta-blocking drugs on the lipid profile: Are diuretics outclassed as initial therapy for hypertension? Am Heart J 1987; 114 (4 pt 2): 998–1006.

Pak

CYC

Heller

Pearle

Odvina

Poindexter

Peterson

. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological intervention. J Urol 2003; 169: 465–9.

10.

NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994; 272: 1942–8.

11.

Gokce

Baydinc

Ilhan

Alasehirli

Ozkucuk

. Use of random urine samples to estimate total urinary calcium and phosphate excretion. Arch Intern Med 1991; 151: 1587–8.

12.

Phuapradit

Manusook

Lolekha

. Urinary calcium/creatinine ratio in the prediction of preeclampsia. Aust N Z J Obstet Gynaecol 1993;33: 280–1.

13.

Lavocat

Breant

Durr

Frey

Freycon

Varlet

. [Evaluation of urinary calcium/creatinine ratio in premature and full-term newborn infants] French. Pediatrie 1993; 48: 905–9.

14.

Milliez

Tcherdakoff

. Antihypertensive activity of a new agent, indapamide: A double-blind study. Curr Med Res Opin 1997; 3: 9–15.

15.

Lemieux

L'Homme

. The treatment of hypertension with indapamide alone or in combination with other drugs. Curr Med Res Opin 1983; 8 (suppl 3): 87–92.

16.

Borghi

Meschi

Guerra

Novarini

. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 1993; 22 (suppl 6): S78–86.

17.

Martins

Meyers

Whalley

Margolius

Buys

. Indapamide (Natrilix): The agent of choice in the treatment of recurrent renal calculi associated with idiopathic hypercalciuria. Br J Urol 1996; 78: 176–80.

18.

Lemieux

. Treatment of idiopathic hypercalciuria with indapamide. CMAJ 1986; 135: 119–21.

19.

Lalande

Roux

Graulet

Schiavi

De Vernejoul

. The diuretic indapamide increases bone mass and decreases bone resorption in spontaneously hypertensive rats supplemented with sodium. J Bone Miner Res 1998; 13: 1444–50.

20.

Reid

Ames

Orr-Walker

Clearwater

Horne

Evans

. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: A randomized controlled trial. Am J Med 2000; 109: 362–9.

21.

Langford

Blaufox

Borhani

Curb

Molteni

Schneider

. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987; 147: 645–9.

22.

Liang

Fries

. Asymptomatic hyperuricemia: The case for conservative management. Ann Intern Med 1978; 88: 666–70.

23.

Krum

Skiba

Gilbert

. Comparative metabolic effect of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Diabet Med 2003; 20: 708–12.

24.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.

25.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64.

26.

Kostis

Lacy

Hall

Wilson

Borhani

Krieger

. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. The SHEP Study Group. Am J Cardiol 1994; 74: 464–7.

27.

Spence

Huff

Barnett

. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: A direct comparison. Can J Clin Pharmacol 2000; 7: 32–7.